

【DRAWINGS】


【Figure 1】




【Figure 2】



【Figure 3】


A. Experimental schematics
IVIS scan
Day 0
Day 1
IVIS scan
Day 7
IVIS scan
Day 14
IVIS scan
Day 21
IVIS scan
Day 28
Day 29
Necropsy
28 x daily 50mg/kg, Citrate of Compound 1 or vehicle (H2O), PO
* 1x 10^6 of GTFB 1016-ola resistant GFP-luc cells were injected into orthotopic intrabursal right ovary with surgery
B.
Week 4 IVIS scan
Fluorescence intensity
strong
weak
Control
Citrate of Compound 1
C.
Control
Citrate of Compound 1
% Change in Flux
p=0.02
IVIS week
D.
p = 0.08
# Nodules
Control
Citrate of Compound 1
Number of tumor nodules
E.
**
Ascites Cell Volume (μl)
Control
Citrate of Compound 1
Ascites cell volume

【Figure 4】


Anti-tumor effect of Citrate of Compound 1 in the Olaparib refractory PDX model
cancer cells
in the ascites
Ascites in ovarian
cancer patients
with acquired
resistance to olaparib
Cancer cell culture
CHA-OVA-13
Olaparib refractory patient
6th line Olaparib treatment →
PR → PD(PFS 7 month)
sBRCA1 mutation
(a)
Olaparib
Olaparib→ Citrate of Compound 1
Citrate of Compound 1
Tumor volume(mm3)
5000
4000
3000
2000
1000
0
0
5
10
15
days
(b)